Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
Quidel Corporation (NASDAQ: QDEL) has announced its participation in two upcoming virtual conferences: the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020. Presentations by CEO Douglas Bryant and CFO Randy Steward will cover business and financial developments. Live webcasts of both events will be available on Quidel's Investor Relations website, with archives accessible for 30 days post-event.
Quidel Corporation has received three prestigious awards from the MarCom Awards competition, recognizing its creative excellence in marketing and communications. Notably, Quidel earned a Platinum Award for its consumer website, “Lyme Disease Answers,” which aims to educate the public about Lyme disease. Additionally, the company won a Gold Award for its upcoming series of educational videos titled “Quick Takes,” aimed at enhancing knowledge among healthcare professionals and consumers. Quidel's Sofia® 2 Lyme FIA test continues to lead in rapid Lyme disease testing, providing quick results to facilitate timely treatment.
Quidel Corporation (NASDAQ:QDEL) will host its Investor Day 2020 virtually on November 12, 2020, starting at 8:00 a.m. PT. The event will feature a management presentation followed by a Q&A session, where the company will discuss key business and financial developments.
To participate, register at Quidel's Investor Relations page or via the presentation link. A live webcast and replay will be available on the company's website for 90 days.
Quidel Corporation (NASDAQ: QDEL) will announce its third fiscal quarter 2020 financial results after market close on October 29, 2020. CEO Douglas Bryant and CFO Randy Steward will host a conference call at 5:00 p.m. ET to discuss these results and address investor questions. The live call will be accessible by phone or webcast, with a replay available for one year on the website and for 14 days via telephone. Quidel focuses on rapid diagnostic testing and aims to enhance healthcare outcomes globally.
Quidel Corporation (NASDAQ: QDEL) has received Emergency Use Authorization (EUA) from the FDA for its Sofia® 2 Flu + SARS Antigen FIA, a rapid test for detecting SARS-CoV-2 and influenza viruses. This single test provides results in just 15 minutes from a nasal swab, promoting timely and accurate diagnosis. Quidel's test shows a 95.2% positive predictive accuracy for SARS-CoV-2 and significant sensitivity for influenza strains, addressing the challenge of overlapping symptoms during flu season. The company aims to enhance diagnostic speed and accuracy in healthcare settings.
Quidel Corporation (NASDAQ: QDEL) announced anticipated third-quarter revenues ranging from $475 million to $477 million, driven by increased demand for COVID-19 diagnostic products. The CEO highlighted the company’s role in enhancing testing accessibility and expects revenues to exceed $800 million in the last quarter of 2020. A virtual Investor Day is scheduled for November 12, 2020, where management will discuss significant business developments. Full financial results will be released in late October 2020.
Quidel Corporation (NASDAQ: QDEL) supports the U.S. Administration's initiative to provide COVID-19 rapid tests to school children. The company is ramping up production of its Sofia® rapid antigen tests, currently at two million tests per week, with plans to double this capacity. The aim is to reach a production run-rate of over 220 million tests per year by July 2021. Quidel's Sofia® tests are made in America, and the company emphasizes the importance of collaboration within the medical diagnostics industry during the pandemic.